After his medicinal chemistry PhD and a Marie Curie Fellowship at Utrecht University, Lluis Ballell Pagès joined GlaxoSmithKline in 2005 to lead different preclinical infectious diseases projects and setup the Open Lab. This role was followed by Malaria Discovery Unit Head overseeing 60 scientists focusing on discovery and early development activities in Malaria, TB and Bacterial Infections (two of those assets currently in Phase II). In September 2021 he joined Janssen GPH group as Clinical Development Team Leader (CDTL) and in March 2023 was appointed R&D Lead for Bacterial Pathogens. He is the author or co-author of over 100 peer reviews papers.
Conflict of Interest: Receives salary from, and has an ownership interest in, Johnson & Johnson.